12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

SBC-103 regulatory update

The European Commission granted Orphan Drug designation for Synageva's SBC-103 to treat mucopolysaccharidosis IIIB (MPS IIIB,...

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >